Mecasermin is a human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology. Insulin-like growth factor-1 (IGF-1) is the principal hormonal mediator of statural growth. Mecasermin is indicated for the long-term treatment of growth failure in patients with confirmed severe primary insulin-like growth factor-1 deficiency (Primary IGFD).
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H01AC03 | Mecasermin | H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01A Anterior pituitary lobe hormones and analogues → H01AC Somatropin and somatropin agonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| INCRELEX Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Mecasermin is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Cyprus (CY)Ecuador (EC)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Israel (IL)Italy (IT)Japan (JP)Lithuania (LT)Netherlands (NL)Poland (PL)Romania (RO)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
